All News
Filter News
Found 806,114 articles
-
RAPT Therapeutics to Present at the UBS Global Healthcare Virtual Conference
5/20/2021
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference
-
Heat Biologics Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer; Selected for Presentation at 2021 American Society of Clinical Oncology Annual Meeting
5/20/2021
Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that the latest data from HS-110, the Company’s lead product, has been accepted for poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8, 2021.
-
BioLineRx to Report First Quarter 2021 Results on May 26, 2021
5/20/2021
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended March 31, 2021 on Wednesday, May 26, 2021
-
Jazz to Present New Data at ASCO and EHA 2021 Meetings Showcasing Clinical Advances Across Hematology and Oncology Portfolio
5/20/2021
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that it and its investigator sponsors will present four new abstracts at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting from June 4 – June 8, 2021 and five abstracts at the virtual 26th Annual Congress of the European Hematology Association (EHA2021) from June 9 –16, 2021.
-
Brooks to Participate in the Jefferies Virtual Healthcare Conference
5/20/2021
Brooks Automation, Inc. (Nasdaq:BRKS) announced today that company management will participate in the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 which includes a webcast beginning at 9:00 a.m. ET . The live webcast can be accessed through the Brooks investor relations website at www.brooks.investorroom.com/e
-
Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis
5/20/2021
Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS ™ (voclosporin) in Subjects with Lupus Nephritis - Individuals treated with LUPKYNIS sustained meaningful reductions in proteinuria with no change in mean eGFR at 104 weeks of treatment -
-
Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis
5/20/2021
Highlights of Recent Positive Data from Nyxol’s Phase 3 Registration Trial Roundtable Discussion by 3 KOLs with Unique Perspectives and Distinct Patient Populations Webinar on Wednesday, May 26 th @ 1:00 pm EDT
-
Invitae to Present at the William Blair 41st Annual Growth Stock Conference
5/20/2021
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the William Blair 41st Annual Growth Stock Conference on Thursday, June 3, 2021 at 3:20 p.m. Central / 4:20 p.m. Eastern / 1:20 p.m. Pacific.
-
Phosplatin Therapeutics Reports Phase 1b Study Results of Immunogenic Cell Death Inducer PT-112 Plus PD-L1 Inhibitor avelumab in Metastatic Prostate Cancer at ASCO Annual Meeting
5/20/2021
Subset Analysis of mCRPC Patients in PT-112-103-PAVE-1 Study Shows PT-112 in Combination with Avelumab is Well Tolerable with Anti-Tumor Effects
-
IQVIA CFO, Ron Bruehlman, to Speak at the William Blair Growth Stock Conference on June 2, 2021
5/20/2021
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will participate in a virtual fireside chat at the William Blair Growth Stock Conference on Wednesday, June 2, 2021 at 10:20 a.m. EDT.
-
RedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021
5/20/2021
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2021 financial results and operational highlights on Thursday, May 27, 2021 .
-
Foundation Medicine and Collaborators to Share New Data During ASCO21 Showcasing the Clinical Utility of Genomic Testing and Its Role in Informing Treatment Decisions Across Ancestry and Disease Type
5/20/2021
Foundation Medicine, Inc . today announced that the company and its collaborators will present a total of 29 studies, including two clinical science symposia presentations and two poster discussions, at the 2021 American Society of Clinical Oncology Virtual Scientific Program (ASCO21) from June 4-8.
-
Affimed Announces Virtual Annual General Meeting of Shareholders
5/20/2021
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2021 Annual General Meeting of Shareholders (the “Annual Meeting”) will be held on June 15, 2021 at 17:30 PM CET (11:30 AM EDT).
-
NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting
5/20/2021
NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that new data from two clinical trials evaluating the company’s lead asset NT-I7 (efineptakin alfa) will be presented during poster sessions at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in a virtual platform June 4-8, 2021.
-
Checkmate Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
5/20/2021
Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger, CEO, will present at the Jefferies Virtual Healthcare Conference from 2:00-2:25pm ET on Tuesday, June 1, 2021. Checkmate will also host 1x1 investor meetings during the conference.
-
Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021
5/20/2021
Olutasidenib demonstrated a 33.3% composite complete remission rate (CR/CRh) in people living with R/R AML with the IDH1 mutation Among those with CR/CRh, estimated 18-month survival is 87%; median overall survival has not yet been reached Duration of response of 13.8 months is longest reported in this treatment setting to date
-
Arvinas to Present at the UBS Global Healthcare Virtual Conference
5/20/2021
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on Tuesday, May 25 at 10:00 a.m. ET.
-
ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference
5/20/2021
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Virtual Healthcare Conference. The presentation is scheduled for June 2, 2021 at 9:30am ET.
-
Ribon Therapeutics Announces Oral Presentation of RBN-2397 Clinical Data at 2021 ASCO Annual Meeting
5/20/2021
Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that data from its first-in-human Phase 1 trial evaluating RBN-2397, its small molecule inhibitor of PARP7, as a monotherapy in patients with advanced solid tumors was selected for an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Intensity Therapeutics Announces Two Abstracts to Be Presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
5/20/2021
Intensity Therapeutics Announces Two Abstracts to Be Presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting